Onset: 15-45 min for capsule/tablet; faster (5-15 min) if a buccal/sublingual form exists (most ENFINITY products are oral capsules).

Peak: ~1-2 hours post-dose, similar to caffeine.

Caffeine-naive at 200mg paraxanthine (the user day-1 archetype):

• Alertness rise comparable to 100-150mg caffeine, on the same 20-30 min timeline.
• Markedly less peripheral activation than equivalent caffeine — most user reports describe HR rise of 3-8 bpm (vs 5-15 bpm for equivalent caffeine), no hand tremor at 200mg in caffeine-naive users, less subjective "warm flush" or sympathetic activation.
• Cognitive feel: clean focus, faster context switching, easier task initiation. Less "stim push" than caffeine — closer to a stim-light or "flat" alertness without the kick. Some users report this as a negative (less subjectively rewarding/motivating) and others as a positive (more sustainable for long cognitive work blocks).
• Mood lift is present but milder than caffeine. The "let's go" feel of caffeine's A2A→DA disinhibition is dampened, which fits the slight A2A-leaning profile (paradoxically — at the receptor level, you'd expect more striatal effect, but in practice the absence of theophylline/theobromine sympathomimetic backdrop reduces the overall arousal sensation).
• Plateau: 2-4 hours of clean cognitive runway at 200mg, vs 3-6 hours for equivalent caffeine. Faster taper.

Caffeine-naive at 300mg paraxanthine + 200-400mg L-theanine (the smoothed protocol):

• Similar lift, even cleaner peripheral profile. Theanine's adrenergic-smoothing effect stacks the same way it does with caffeine. Probably the cleanest available "stim cocktail" subjective experience for cognitive work.

Caffeine-experienced user at 200mg paraxanthine:

• Most caffeine-habituated reviewers describe paraxanthine as subjectively weaker than equivalent caffeine at the 1:1 mg level — confirming that 200mg paraxanthine ≈ 100-150mg caffeine on perceived intensity. To match a caffeine-equivalent feel, dose 300mg paraxanthine ≈ 200mg caffeine is a more accurate equivalence.
• The "no crash" claim is partially borne out — short half-life means less of a hard taper, but also means a shorter window of effect. Some users feel the "fade" more than the "crash."

Honest variability: Same fundamental adenosine-blockade variance applies. ~5-10% of users get more anxiety than benefit at 300mg+, especially anxiety-prone or ADORA2A TT genotypes. Slow-CYP1A2 phenotype is not relevant to paraxanthine half-life (unlike caffeine), which is one of the genuinely useful pharmacogenomic distinctions.

• Tolerance buildup: FAST — assume identical to caffeine. Adenosine A1 + A2A receptor upregulation begins within 3-7 days of daily dosing. The Compound Solutions marketing claim that "paraxanthine doesn't build tolerance" is mechanistically implausible and contradicted by basic adenosine pharmacology. Until there's a rigorous head-to-head 6-12 week tolerance study showing paraxanthine spares the upregulation that caffeine produces, treat tolerance assumptions identically.
• Recommended cycle for users in this archetype: 2-4 days on, 3-5 days off pattern. Same as caffeine. PRN use preserves the responder window indefinitely.
• Reset protocol if tolerance develops: 7-14 days complete abstinence for adenosine receptor density to renormalize. Same as caffeine.
• Caffeine + paraxanthine cross-tolerance: Yes. Both compounds blockade the same receptors. Dosing 4 days/week of caffeine + 4 days/week of paraxanthine = effectively 8 days/week of methylxanthine = no rest day. Don't trick yourself into thinking they're independent compounds — they aren't.

Synergistic with

• l-theanine (1:1 to 1:2 ratio, 200-400mg theanine per 200mg paraxanthine): Same logic as the caffeine + theanine pairing. Theanine's alpha-wave / GABA-A modulation smooths any residual adrenergic edge while preserving the alerting effect. Already in the user's V stack. Mandatory pairing.
• l-tyrosine (500mg-2g, 30-60 min before paraxanthine): Mechanistic synergy parallel to caffeine + tyrosine. Paraxanthine's A2A blockade increases striatal DA tone → tyrosine supplies the precursor. PRN, not daily.
• Citicoline / Alpha-GPC (V4 baseline): Cholinergic + methylxanthine pairing is generally clean.

Avoid stacking with

• Caffeine on the same day: additive adenosine blockade. Pick one per day.
• Other adenosine-receptor antagonists (KW-6356 if/when launched, theophylline-class compounds): additive, not synergistic.
• High-dose other stimulants (amphetamine, methylphenidate, high-dose synephrine, yohimbine): cumulative sympathetic load.
• modafinil on day-1 onboarding of either compound: layer cautiously. Once the user establishes modafinil baseline (week 4-8), 200mg paraxanthine + theanine layered on modafinil days is reasonable — and may actually be a better cardiovascular pairing than caffeine + modafinil given paraxanthine's smaller HR/BP load. Track HR/BP.
• PM dosing past 6h pre-bed: even paraxanthine's shorter half-life produces residual A1/A2A blockade at sleep onset. Respect the cutoff.
• Hard-spar Saturdays: same caveat as caffeine — combat sport reaction-consistency literature (Diaz-Lara) hasn't been replicated for paraxanthine, but no mechanistic reason to expect a different reaction-variance profile.

Neutral / safe co-administration

• All the user's V stack supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, glycine/tryptophan, D3/K2, beta-alanine, vitamin C) — no interactions of concern.
• Most peptides (BPC-157, TB-500, Semax, Selank, Adamax) — neutral.
• Most Russian nootropics (bromantane, phenylpiracetam, sulbutiamine) — neutral.

Paraxanthine's metabolic profile (the practical advantage over caffeine):

• NOT a CYP1A2 substrate — paraxanthine is the product of caffeine's CYP1A2 demethylation, not further methylated by CYP1A2.
• Cleared via further demethylation to 1-methylxanthine and oxidation by xanthine oxidase to 1-methyluric acid. Minor pathways via CYP2A6 and N-acetyltransferase 2 (NAT2).
• Practical implication: paraxanthine clearance is independent of CYP1A2 induction/inhibition state. Smokers, cruciferous-veg-heavy diet, oral-contraceptive users, fluvoxamine users — all have the same paraxanthine kinetics. This is the most concrete pharmacological advantage of paraxanthine over caffeine.

Clinically significant interactions (much smaller surface than caffeine):

1. Xanthine oxidase inhibitors (allopurinol, febuxostat — for gout) — theoretically slow paraxanthine clearance via the 1-methylxanthine → 1-methyluric acid step. Not relevant-to-archetype; flagged for completeness.
2. NAT2 inhibitors / poor metabolizers — minor effect on clearance. Pharmacogenomically relevant for a small subset.
3. Adenosine (IV during cardiac stress test) — paraxanthine antagonizes the response, same as caffeine. Avoid 24h pre-stress test.
4. MAOIs (non-selective) — theoretical hypertensive risk, parallel to caffeine. Selegiline at MAO-B-selective doses fine.
5. Lithium — diuretic effect mildly increases lithium clearance. Same as caffeine.
6. Iron absorption — likely the same chelation effect as caffeine on non-heme iron. Space iron + paraxanthine 1-2h apart.

Notable non-interactions (vs caffeine):

• Hormonal contraceptives — do NOT prolong paraxanthine half-life (whereas they prolong caffeine half-life ~50% via CYP1A2 inhibition).
• Smoking, cruciferous vegetables, charred meats — do NOT affect paraxanthine clearance (whereas they accelerate caffeine clearance via CYP1A2/AHR induction).
• Fluvoxamine — does NOT increase paraxanthine AUC (whereas it 5-10× increases caffeine AUC).
• Modafinil-induced CYP1A2 induction — does NOT affect paraxanthine. This is genuinely useful for the user's V stack modafinil + stim layering.

This is where paraxanthine has a real, concrete advantage over caffeine for an unknown-phenotype user.

CYP1A2 rs762551 — irrelevant to paraxanthine clearance.

• Whatever the user's 23andMe (~June 5-15, 2026) reveals for CYP1A2, paraxanthine kinetics don't change. Slow metabolizer (CC) caffeine response — the worst-case caffeine phenotype — does not apply to paraxanthine.
• For the user: if the 23andMe result returns CC, paraxanthine becomes a markedly more attractive choice than caffeine as the cognitive-stim baseline. Caffeine drops to once/twice-weekly tool; paraxanthine could move up to 3-4 days/week PRN.

ADORA2A rs5751876 — applies identically to paraxanthine.

• Both caffeine and paraxanthine antagonize A2A. ADORA2A TT carriers will likely show the same anxiety-prone response to paraxanthine that they show to caffeine. Theanine pairing remains important.

AHR rs6968865 / rs4410790 — irrelevant to paraxanthine clearance.

• AHR governs CYP1A2 induction. Paraxanthine doesn't go through CYP1A2 for clearance, so AHR phenotype doesn't matter. Concrete advantage for users whose diet/lifestyle changes affect their caffeine kinetics.

COMT Val/Val vs Met/Met — applies similarly to paraxanthine.

• Same A2A → DA disinhibition mechanism, so same COMT-modulated downstream response.

Practical archetype-specific takeaway (pre-23andMe):

• Paraxanthine is a phenotype-robust methylxanthine. No matter what the 23andMe result reveals for CYP1A2/AHR, paraxanthine kinetics are predictable.
• If 23andMe returns CYP1A2 CC (slow metabolizer): paraxanthine becomes the preferred methylxanthine. Move it up the priority list.
• If 23andMe returns CYP1A2 AA (fast metabolizer): caffeine remains a great choice, paraxanthine is a niche backup for late-day use cases.

For the user: NOW Foods or Nutricost 200mg capsules from Amazon/iHerb are the canonical pick. ~$0.40-0.60/dose at 2-4 doses/week = $4-10/month. Negligible budget impact vs V4/V5 baseline. Can order as a V5 add-on after caffeine baseline is characterized.

Cost comparison vs caffeine + theanine:

• Caffeine + theanine PRN: ~$0.10-0.20/dose total (caffeine tablet ~$0.05, theanine cap ~$0.10). Already in V4.
• Paraxanthine + theanine PRN: ~$0.50-0.70/dose total. 3-5× more expensive than caffeine + theanine.
• For the user's budget, this is trivial. The real question is whether the cleaner profile is worth the marginal cost — and the answer is "probably yes for late-day or pre-MMA use cases, probably no for AM cognitive blocks where caffeine + theanine handles it fine."

Baseline (before starting)

• Resting HR + BP (3-day morning average) — paraxanthine adds 3-8 bpm, smaller BP rise than caffeine.
• Subjective sleep quality VAS for 7 days pre-dose.
• Anxiety baseline (GAD-7 or daily 1-10 VAS).
• Oura/sleep-tracker baseline for 14 nights.
• If a user in this archetype has a caffeine baseline established: track paraxanthine subjective and objective response side-by-side with caffeine at equivalent doses (e.g., 200mg paraxanthine vs 100mg caffeine on alternate weeks) to characterize personal preference.

During use

• First 2 weeks: daily HR/BP morning + post-dose to characterize personal response.
• Daily Oura/sleep tracking — compare on-days vs off-days. Specifically track REM/deep sleep even with the shorter half-life — the subjective-objective disconnect risk applies to paraxanthine too.
• Weekly subjective cognitive performance VAS on use-days vs rest-days.
• Anxiety daily VAS.
• Side-by-side comparison weeks (paraxanthine vs caffeine): the cleaner-profile claim is testable in n=1 with Oura HR + Oura sleep + subjective VAS. This is the most useful archetype-specific experiment paraxanthine enables.

Post-cycle (if cycled / abstinent week)

• Note withdrawal severity days 1-3. Should be milder than caffeine withdrawal (shorter half-life, less prolonged receptor blockade).
• Sleep-tracker recovery within 1-2 nights.